Rosalind Advisors, Inc.
Long book
$244.1M
Q1 2026
Positions
32
Top-10 weight
67%
concentration
Last quarter
+18.4%
SPY +14.8%
Turnover
48%
of book per quarter
Strategy in plain words
auto-generated from filingsRosalind Advisors, Inc. is a concentrated fundamental stock-picker, specialised in healthcare (90% of the long book), running a $244.1M US long book across 32 positions.
The portfolio is concentrated: the top 10 names carry 67% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: DELCATH SYSTEMS INC, XERIS BIOPHARMA HOLDINGS INC, FENNEC PHARMACEUTICALS INC, SAVARA INC, VAXCYTE INC.
Over the last 9 quarters its long book ran on average 1.1pp per quarter behind the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-14.5%
Q2 2024
+10.3%
Q3 2024
+2.1%
Q4 2024
-2.5%
Q1 2025
+2.4%
Q2 2025
+23.1%
Q3 2025
+3.7%
Q4 2025
-12.5%
Q1 2026
+18.4%
Sector allocation
Healthcare 90%
Materials 10%
Long book by quarter
What does Rosalind Advisors, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| DCTH DELCATH SYSTEMS INC | Healthcare | 3.3M | $30.6M | 12.5% | Held |
| XERS XERIS BIOPHARMA HOLDINGS INC | Healthcare | 3.2M | $18.7M | 7.7% | +53.0% |
| FENC FENNEC PHARMACEUTICALS INC | Healthcare | 2.9M | $17.9M | 7.3% | +11.3% |
| SVRA SAVARA INC | Healthcare | 3.2M | $17.5M | 7.2% | -5.9% |
| PCVX VAXCYTE INC | Healthcare | 290.0K | $16.9M | 6.9% | New |
| EYPT EYEPOINT INC | Healthcare | 1.0M | $13.4M | 5.5% | +50.3% |
| XFOR X4 PHARMACEUTICALS INC | Healthcare | 3.2M | $13.3M | 5.4% | +23.4% |
| VOR VOR BIOPHARMA INC | Healthcare | 700.0K | $12.5M | 5.1% | New |
| MDWD MEDIWOUND LTD | Materials | 749.1K | $12.1M | 4.9% | Held |
| VSTM VERASTEM INC | Healthcare | 2.1M | $11.3M | 4.6% | +19.6% |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 330.0K | $10.5M | 4.3% | New |
| BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 923.1K | $8.8M | 3.6% | New |
| HELP CYBIN INC | Healthcare | 1.5M | $7.4M | 3.0% | -7.6% |
| CGON CG ONCOLOGY INC | Healthcare | 100.0K | $6.8M | 2.8% | -66.7% |
| NSPR INSPIREMD INC | Healthcare | 3.9M | $6.4M | 2.6% | Held |
| AVIR ATEA PHARMACEUTICALS INC | Healthcare | 1.2M | $6.3M | 2.6% | New |
| PROF PROFOUND MEDICAL CORP | Healthcare | 828.1K | $5.4M | 2.2% | -22.5% |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 250.4K | $4.9M | 2.0% | -44.4% |
| PYPD POLYPID LTD | Healthcare | 597.9K | $2.6M | 1.1% | -14.2% |
| MYO MYOMO INC | Healthcare | 3.8M | $2.6M | 1.1% | +0.2% |
| TLPH TALPHERA INC | Healthcare | 3.4M | $2.5M | 1.0% | -6.3% |
| OVID OVID THERAPEUTICS INC | Healthcare | 1.1M | $2.5M | 1.0% | New |
| DFTX DEFINIUM THERAPEUTICS INC | Materials | 125.0K | $2.4M | 1.0% | New |
| OKUR ONKURE THERAPEUTICS INC-A | Healthcare | 443.8K | $1.8M | 0.8% | -39.3% |
| LPCN LIPOCINE INC | Healthcare | 221.6K | $1.8M | 0.7% | New |
| NRXS NEURAXIS INC | Healthcare | 286.1K | $1.7M | 0.7% | Held |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 75.0K | $1.1M | 0.5% | New |
| ANNX ANNEXON INC | Healthcare | 200.0K | $1.1M | 0.5% | New |
| AQST AQUESTIVE THERAPEUTICS INC | Healthcare | 250.0K | $1.0M | 0.4% | New |
| BFRI BIOFRONTERA INC | Healthcare | 1.2M | $942K | 0.4% | +2.0% |
| KURA KURA ONCOLOGY INC | Healthcare | 100.0K | $813K | 0.3% | Held |
| RGNT REGENTIS BIOMATERIALS LTD/IS | Healthcare | 251.5K | $768K | 0.3% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 38 | $248.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 12, 2026 | 42 | $284.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 39 | $292.6M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 37 | $210.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 34 | $205.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR/ARESTATEMENT | Feb 14, 2025 | 40 | $195.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 11, 2025 | 40 | $195.6M | SEC ↗ | |
| Q3 2024 | 13F-HR | Oct 30, 2024 | 33 | $156.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Jul 12, 2024 | 40 | $130.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | Apr 25, 2024 | 34 | $107.0M | canonical | SEC ↗ |